Clinical trials: Moderate-to-severe Psoriasis
Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT07672561
- Testing
- Drug:WD-890
- Where
- China
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Zhejiang Wenda Pharma Technology LTD.
Healthy Subjects
Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis
The purpose of this study is to establish if BMS-986165 is safe and effective at treating autoimmune diseases. BMS-986165 which has shown some promise in preclinical studies for inhibiting autoimmune conditions.
- Trial name
- NCT02534636
- Testing
- BMS-986165, Interferon alpha-2a recombinant, Famotidine
- Where
- Australia
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Chronic Plaque Psoriasis
Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis
It is a phase IV multicentric, placebo-controlled, clinical trial investigating the efficacy and safety of acitretin combined to efalizumab in the therapy of chronic plaque psoriasis.
- Trial name
- CobAcE (NCT00707070)
- Testing
- efalizumab plus acitretin
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universita di Verona
Plaque Psoriasis
A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis
An open label, single arm study to evaluate the study and efficacy of efalizumab in combination with NB-UVB. Weeks 1-12 efalizumab will be administered once a week in combination with NB-UVB three times per week.
- Trial name
- NCT00302445
- Testing
- Efalizumab, Narrow Band Phototherapy
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Derm Research, PLLC
Psoriasis
Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis
The purpose of this study is to establish if BMS-986202 is safe and effective at treating autoimmune diseases such as psoriasis.
- Trial name
- NCT02763969
- Testing
- BMS-986202, Interferon alpha-2a recombinant, Famotidine
- Where
- 2 sites in Australia
- Volunteers
- 357 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis
The purpose of this study is to determine if infliximab (anti-TNF) is effective in the treatment of plaque psoriasis.
- Trial name
- NCT00106834
- Testing
- Infliximab
- Volunteers
- 378 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Psoriasis
A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis
The purpose of this study is to evaluate the safety and how the body affects a drug (CNTO 1959) in healthy volunteers and in patients with psoriasis.
- Trial name
- NCT00925574
- Where
- 8 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Parapsoriasis, Healthy Volunteers
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
To evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of CC-90005 in healthy subjects and subjects with moderate to severe plaque-type psoriasis.
- Trial name
- NCT02502188
- Testing
- CC-90005
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celgene
Scalp Psoriasis
Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis
- Trial name
- NCT02933502
- Testing
- DSXS topical product
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Moderate-to-Severe Plaque Psoriasis
A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices
The purpose of this study is to evaluate the safety and pharmacokinetics of SHR-1314 injection in healthy subjects at different specifications devices.
- Trial name
- NCT06182384
- Testing
- SHR-1314
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Plaque Psoriasis, Healthy Volunteer
A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and food effect of UA026 tablets.
- Trial name
- NCT07038720
- Testing
- UA026
- Where
- China
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Usynova Pharmaceuticals Ltd.
Moderate to Severe Plaque Psoriasis
A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of SHR-1139 injection in healthy subjects who receive a single subcutaneous injection or intravenous infusion of…
- Trial name
- NCT07051538
- Testing
- SHR-1139 Injections
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with…
- Trial name
- BE UNIQUE (NCT06506916)
- Testing
- bimekizumab
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Psoriasis
Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the safety and effectiveness of CNDO 201Trichuris suis ova (TSO) for the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT01836939
- Testing
- TSO 2500, TSO 7500
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Mark Lebwohl
Plaque Psoriasis
The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab
To describe the response of etanercept after adalimumab has failed to produce a satisfactory response in moderate to severe plaque psoriasis.
- Trial name
- NCT00833729
- Testing
- etanercept
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Dermatrials Research
Plaque Psoriasis, Psoriatic Arthritis
Modifying PEST for Psoriatic Arthritis Screening
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
- Trial name
- ScreenX (NCT06382051)
- Testing
- PEST Screening group
- Where
- 30 sites in Canada
- Volunteers
- 502 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
This will be a single-center, open-label clinical study to determine the efficacy and safety of secukinumab in the treatment of moderate to severe psoriasis vulgaris in skin of color (SOC) (FST IV-VI).
- Trial name
- NCT04571567
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Saakshi Khattri
Psoriasis
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers
This is Part 1 of a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 was administered to participants; Part 1 in healthy volunteers and Part 2 in psoriatic participants.
- Trial name
- NCT03724292
- Testing
- VTP-43742
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vitae Pharmaceuticals Inc., an Allergan affiliate
Moderate-to-severe Psoriasis
The Relationship Between Moderate-to-severe Psoriasis and Sleep Disturbance
Psoriasis is a common chronic and systemic immune-mediated disease, induced by a combination of genetic and environmental effects.
- Trial name
- NCT06165887
- Testing
- No intervention
- Where
- China
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Chronic Plaque Psoriasis
To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital
This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly…
- Trial name
- NCT07337434
- Testing
- Methotrexate, Apremilast
- Where
- Pakistan
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Syeda Sana Zaman